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The gene coding for the S protein, the smaller of the two envelope antigens of the duck hepatitis B virus
(DHBV), is transcribed from a TATA-less promoter. In this study, we localized the promoter to a 245-bp
segment of the genome that was capable of efficiently driving expression of a linked reporter gene upon
transient transfection into the differentiated hepatoma cell lines LMH and HepG2. However, no measurable
activity from this construct could be detected in similar assays with the dedifferentiated cell line HepG2.1 or
the nonhepatic cell line HeLa. Located at position 225 relative to the transcriptional start site was a sequence
conforming to the consensus binding site for hepatocyte nuclear factor 3 (HNF3). Deletion of this region
reduced activity of the reporter gene to barely detectable levels in LMH cells. The results of electrophoretic
mobility shift analysis (EMSA) demonstrated that a double-stranded oligonucleotide containing this sequence
formed a specific complex with DNA-binding proteins from LMH and HepG2 cells but not with nuclear extracts
obtained from HepG2.1 or HeLa cells. Cotransfection of HepG2.1 cells with DHBV S promoter constructs and
a rat HNF3b expression plasmid resulted in transactivation of only those constructs in which the candidate
HNF3 site was present. Furthermore, EMSA using HepG2.1 nuclear extracts containing exogenously expressed
HNF3 formed complexes with the same migration and competition properties as those in which the proteins
were derived from the differentiated hepatoma cells. Thus, several lines of evidence suggest a critical role for
HNF3 in activity from the DHBV S promoter.
Hepadnaviruses are a family of DNA-containing enveloped
animal viruses for which the prototype is the hepatitis B virus
(HBV) of humans. Other members include the woodchuck
hepatitis virus, duck HBV (DHBV), and heron HBV. These
viruses display a pronounced tissue tropism, with replication
occurring primarily in hepatocytes, a specificity which is
thought to reflect both the presence of appropriate receptors
on the surfaces of hepatic cells and the requirement for liver-
enriched transcription factors for the coordinate production of
viral mRNAs. Indeed, diverse studies on transcription from
HBV promoters have demonstrated that numerous liver-en-
riched proteins play roles in the regulation of at least some of
these promoters (4, 5, 11, 14, 22, 23).
For all hepadnaviruses, the template for viral RNA tran-
scription in productive infections is a unit-length covalently
closed circular DNA molecule, initially formed from the re-
laxed open circular genome of the infecting virus. In DHBV-
infected hepatocytes, three distinct mRNAs are synthesized
from the covalently closed circular DNA template: a 3.3-kb
transcript termed the pregenome, from which the nucleocapsid
and polymerase polypeptides are translated, and the two en-
velope mRNAs of 2.3 and 2.1 kb, from which the pre-S and S
proteins, respectively, are produced. Though one open reading
frame encodes both envelope proteins, the mRNAs from
which they are translated are initiated at separate regions of
the genome and thus are assumed to be under control of
distinct promoters. The pre-S promoter contains a canonical
TATA motif, whereas the S mRNA is not governed by a
recognizable TATA sequence. Moreover, the S promoter is
buried within the coding region for both the larger pre-S
polypeptide and, in a different translation frame, the polymer-
ase protein. Thus, the sequences directing transcription of the
2.1-kb mRNA must function in two alternative contexts.
Many aspects of hepadnaviral replication and biology have
been dissected by using DHBV as a model; however, relatively
few studies have addressed the regulation of its genes. Studies
with transfected cell cultures have tentatively identified some
of the cis elements involved in transcription of the mRNAs (3,
9, 17, 24); however, the transcription factors which interact
with the promoters have not been extensively characterized. A
region upstream of the DHBV nucleocapsid promoter has
been described as a liver-specific enhancer (9, 17, 24), and
liver-enriched transcription factors have been demonstrated to
recognize binding sites within the enhancer region (16, 18).
Only one of these studies (17) examined the effects of the
enhancer on the DHBV promoters. That report concluded
that the enhancer augmented the activity of a DHBV minimal
nucleocapsid promoter construct and had no effect on activity
from the pre-S promoter but was essential for expression from
the S promoter.
Whereas gene regulation studies of the DHBV system are in
their infancy, numerous studies have investigated the se-
quences responsible for regulation of transcription from the
HBV promoters (4, 5, 11, 14, 21–23, 25). Diverse studies have
indicated that the HBV S promoter is active in both liver-
derived and non-liver cell lines (5, 11, 22). Consistent with
these observations is the important role played by Sp1, a ubiq-
uitously expressed transcription factor, in regulating activity
from this promoter (21). In contrast, transcription from the
DHBV S promoter has been described as liver specific, a pref-
erence which has been attributed to the dependence of the
DHBV S promoter on the viral enhancer (17).
The work presented here describes the identification of a
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key regulatory sequence in the DHBV S promoter. We have
employed deletion analysis of a unit-length copy of the DHBV
genome in transient-expression experiments to examine the
expression of a linked reporter gene from the DHBV S pro-
moter. We found that while the DHBV S promoter displayed
a requirement for differentiated hepatocytes, the DHBV en-
hancer was not necessary for expression from the S promoter
in our assay system. We observed that a DHBV fragment of
245 bp (positions 250 to 1195 relative to the transcription
start site) was necessary and sufficient for high levels of expres-
sion of a reporter gene in transient transfections into LMH or
HepG2 cells. We present evidence that a sequence within this
fragment binds members of the hepatocyte nuclear factor 3
(HNF3) family of liver-enriched proteins and that this binding
site represents a critical component of the DHBV S promoter.
MATERIALS AND METHODS
Plasmid constructions. The steps used for construction of the various plasmids
used in the transient-transfection experiments followed standard molecular bi-
ology protocols (1). The DHBV sequences in these constructions were derived
from pBR322-p2.3 (GenBank accession no. M60677), which contains a head-to-
tail dimer of the viral DNA sequence inserted at the EcoRI site of pBR322. The
chloramphenicol acetyltransferase (CAT) reporter plasmid was the promoterless
pCATBasic vector (Promega). The plasmid pBS was created by digestion of
pBR322-p2.3 at a unique DHBV XhoI site and cloning the unit-length genomic
fragment into the SalI site of pCATBasic. The unique XhoI site is situated
between the reported cap site for the S transcript at nucleotide 984 and the
methionine codon at nucleotide 1284 (3). Therefore, pBS contains the complete
DHBV genome (coordinates 1213 to 3021 and 1 to 1217) permuted such that
transcription of the CAT gene is controlled by the DHBV S promoter. Deletions
from the 59 end of the DHBV genome in pBS were generated by excising
selected sequences between restriction endonuclease sites. Where this was not
feasible, PCR was used to engineer appropriate restriction sites at the ends of
desired DHBV fragments, followed by cloning steps similar to those used for
pBS. Mutation of the pre-S TATA box (see Fig. 1B) was achieved by a two-step
overlapping PCR method, in which the TATA sequence at DHBV nucleotide
coordinates 710 to 715, TATAAG, was first altered to a PstI site, CTGCAG, via
two half reactions and 10 cycles of amplification, followed by mixing of the
products and a subsequent 10 cycles of amplification. The incorporation of the
PstI restriction site provided a convenient means for screening plasmid DNA
following bacterial transformation, as there are no native PstI sites in the DHBV
p2.3 genome. Plasmids are designated according to DHBV sequences present in
the construct, using coordinates derived from the GenBank sequence data bank.
All plasmids were purified through two isopycnic centrifugations in CsCl with
ethidium bromide.
Cells and transfections. The chicken hepatoma cell line LMH (6, 15) and the
human hepatoma cell lines HepG2 and HepG2.1 (22) were grown in Dulbecco’s
modified Eagle’s medium–Ham’s F-12 medium (1:1), supplemented with 10%
fetal bovine serum, at 378C in humidified 5% CO2. The human cervical carci-
noma cell line HeLa was grown in Dulbecco’s modified Eagle’s medium plus 4.5
mg of glucose per ml and 10% fetal bovine serum at 378C in 5% humidified CO2.
LMH, HepG2.1, and HeLa cells were transfected by electroporation (1).
Exponentially growing cells were harvested, washed twice with ice-cold phos-
phate-buffered saline (PBS), and suspended to 2 3 107 cells per ml in ice-cold
PBS. The cells were electroporated at 960 mF and 250 V, using a Bio-Rad Gene
Pulser. HepG2 cells were transfected by the calcium phosphate coprecipitation
technique as described previously (1). For both methods, the transfected DNA
mixture consisted of 5 mg of a CAT plasmid and 1 mg of pCMVb (Clontech), an
internal control for transfection efficiency. pCMVb harbors the b-galactosidase
gene of Escherichia coli, under the control of the cytomegalovirus immediate-
early promoter. In certain experiments, the DNA mixture also included 1.5 mg of
the HNF3a or HNF3b expression vector, pCMVHNF3a or pCMVHNF3b,
respectively, or an equivalent amount of empty expression vector pCMV as a
control. Cell extracts were prepared 21 to 24 h posttransfection and assayed for
CAT activity by ascending thin-layer chromatography (1). Chromatograms were
quantitatively scanned by using a radioanalytic imaging system (AMBIS). An
aliquot of each extract was also assayed for b-galactosidase activity by using a kit
from Promega. Within a transfection experiment, the CAT activity of each S
promoter construct was normalized (percent acetylation per unit of b-galactosi-
dase activity) and then compared with the normalized activity of a reference S
promoter construct. The resulting ratio was the relative CAT activity for that
construct. For LMH and HepG2 cells, the reference point was the unit-length
genomic construct pBS. In LMH cells, acetylation values for pBS were generally
between 3 and 7% after subtraction of background acetylation from the empty
pCATBasic vector. All transient-expression assays were performed 2 to 12 times,
using at least two independent plasmid preparations.
Nuclear extracts and electrophoretic mobility shift assays. Nuclear extracts
from LMH, HepG2, and HepG2.1 cells were prepared by using a modified
rapid-lysis protocol (2). All procedures were performed at 0 to 48C with ice-cold
reagents. Cells were scraped into PBS, pelleted, washed twice with PBS, and
resuspended in lysis buffer (10 mM N-2-hydroxyethylpiperazine-N9-2-ethanesul-
fonic acid [HEPES] [pH 7.6], 60 mM KCl, 1 mM EDTA, 1 mM dithiothreitol,
protease inhibitors [2], 0.1% Nonidet P-40). After a 4-min incubation on ice, the
lysates were spun for 4 min at 1,500 rpm in an Eppendorf microcentrifuge at 48C
and the supernatants were removed. The pelleted nuclei were resuspended in
lysis buffer without Nonidet P-40, pelleted by centrifugation at 1,500 rpm for 4
min, then resuspended in nuclear extract buffer (20 mM Tris hydrochloride [pH
8.0], 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM dithiothreitol, 25%
[vol/vol] glycerol, protease inhibitors), and incubated on ice for 10 min with
occasional vortexing. The suspension was pelleted at 48C in an Eppendorf a
microcentrifuge at 15,000 rpm for 10 min, and the supernatant was removed and
dialyzed for 2 h at 48C against dialysis buffer (20 mM HEPES [pH 7.9], 75 mM
KCl, 0.2 mM EDTA, 10% [vol/vol] glycerol, protease inhibitors). The dialysate
was pelleted briefly at 48C, and the supernatant was removed, aliquoted, and
stored at 2708C. Protein concentration was determined by the Bradford assay
(Bio-Rad) against a bovine serum albumin standard. HeLa cell extracts were
purchased from Promega and used as directed. For preparation of extracts
containing exogenously expressed HNF3a or HNF3b, HepG2.1 cells were elec-
troporated with 15 mg of the expression vector 24 h prior to extract preparation.
Electrophoretic mobility shift assays (EMSAs) were carried out essentially as
described elsewhere (1). 32P-labeled double-stranded oligonucleotide (see be-
low) (6 3 1022 pmol) was incubated with 4 mg of nuclear extract prior to 4%
polyacrylamide gel electrophoresis at 48C and autoradiography. When competi-
tion experiments were performed, nuclear extract was preincubated with 9 pmol
of unlabeled double-stranded competitor oligonucleotide for 10 min prior to the
addition of the labeled oligonucleotide.
Oligonucleotides and probes. The double-stranded oligonucleotides used were
synthesized as complementary single strands that spanned selected DHBV se-
quences or comprised previously identified consensus binding sites (see Fig. 3).
In addition to the sequences shown, double-stranded oligonucleotides contained
59 AGCT extensions, which were labeled by filling in with [a-32P]dATP, unla-
beled deoxyribonucleoside triphosphates, and the Klenow fragment of DNA
polymerase.
RESULTS
Deletion analysis of the S promoter. Evaluation of the reg-
ulatory regions governing transcription of the DHBV surface
antigen promoter began with a full-length copy of the DHBV
genome inserted such that the S promoter was immediately
adjacent to and upstream of the CAT gene. The abilities of
constructs with a series of 59 deletions of the DHBV sequence
to direct transcription of the reporter gene were compared,
using transient transfection assays in a variety of cell lines (Fig.
1A). In the chicken hepatoma cell line LMH and the human
hepatoblastoma cell line HepG2, removal of as much as 84%
of the DHBV genome from the parent construct did not have
an adverse effect on transcription of the reporter gene. In fact,
removal of sequences 59 to DHBV nucleotide coordinate 428
resulted in consistent and marked increases in transcriptional
activity compared with that of pBS, as indicated by the in-
creased relative CAT values. The only drop in signal occurred
upon deletion of sequences between positions 428 and 720.
This 2.7-fold reduction may reflect the removal of supplemen-
tal elements modulating the S promoter. Nevertheless, since
the activity of pB720-1217 was at least as strong as the genomic
construct in the differentiated liver cell lines, we concluded
that basal requirements for efficient transcription from the S
promoter were represented in pB720-1217. None of the con-
structs exhibited detectable activity in the dedifferentiated
HepG2.1 or the non-liver HeLa cell line, even when the
amount of transfected construct was increased to 15 mg (data
not shown), though expression from positive-control plasmids,
such as pRSVCAT and pCMVb, indicated that the lack of
signal was not due to problems with the transfection technique.
In addition to the S promoter, pB428-1217 includes the
primary sequences responsible for directing transcription from
the pre-S promoter (3, 17; unpublished observation), including
the pre-S TATA motif. The 59 breakpoint for pB720-1217 lies
immediately downstream of this sequence. Thus, another in-
8814 WELSHEIMER AND NEWBOLD J. VIROL.
terpretation for the increased expression from pB428-1217
could be a positive influence of the pre-S promoter in the form
of read-through into the reporter gene, producing an additive
effect on CAT expression. Consistent with this notion was the
decreased signal from the reporter gene upon deletion of
DHBV sequence between coordinates 428 and 720, including
the TATA box sequence at coordinates 710 to 715. Though the
presence of multiple ATG codons between the pre-S mRNA
cap site at DHBV nucleotide 732 and the CAT protein ATG
more than 400 nucleotides downstream made this possibility
seem unlikely, we nevertheless wished to assess the activity of
the S promoter in the presence of an inactive pre-S promoter.
In previous experiments with the pre-S promoter, we had ob-
served that mutation of the TATA sequence to a PstI site
ablated expression from pre-S promoter constructs (unpub-
lished observation). Thus, we made a series of constructs anal-
ogous to those shown in Fig. 1A but with the pre-S TATA box
replaced by a PstI site and monitored their activities in LMH
cells (Fig. 1B). Expression levels of the altered constructs were
not significantly different from those of the unmutated coun-
terparts; furthermore, they exhibited the same trend in activity
with successive deletions from the 59 end. These observations
indicated that transcription from the pre-S promoter was not
being detected by the transient-expression assays and that the
pre-S promoter was neither a positive nor negative influence
on the transcriptional activity of the S promoter in this system.
The experiments described above demonstrated that pB720-
1217 possessed the necessary components to direct transcrip-
tion from the S promoter in a cell type-specific manner. Ad-
justment to the 39 end of this construct was made by deletion
of sequence between DHBV nucleotide coordinates 1179 and
1217; this alteration did not adversely affect reporter gene
activity in LMH cells (Fig. 2). An additional 59 deletion beyond
the transcription start site at DHBV nucleotide coordinate 984
(3) resulted in loss of signal from the reporter gene (pB1094-
1178 [Fig. 2]), so we concluded that a functional DHBV S
promoter lay between nucleotide coordinates 720 and 1178.
Identification of a sequence upstream of the S mRNA initi-
ation site with properties of an HNF3 recognition site. Since
FIG. 1. Deletion analysis of the DHBV S promoter. The diagram at the top of the figure indicates the orientation of the unit-length DHBV genome permuted so
that the S promoter directs transcription of the CAT gene. Arrows represent the positions and directions of transcription from the pregenome-nucleocapsid (C),
presurface (pS), and surface (S) promoters. Black boxes indicate the enhancer (Enh) and the CAT open reading frame. The activity of each of the various promoter
constructs is reported relative to the activity of the pBS construct, which is set at 1.00. (A) Deletion analysis of the S promoter in LMH, HepG2, HepG2.1, and HeLa
cells. The horizontal lines indicate the DHBV sequences present in the various S promoter constructs. Plasmids are designated according to the DHBV sequences
present in each construct, using nucleotide coordinates derived from the GenBank genetic sequence data bank. (B) Relative activities of the S promoter deletion
constructs in the context of the pre-S TATA box mutation. Inverted arrowheads indicate the locations of the substitution of the PstI site for the TATA box. Plasmids
are designated as described above, with “(PstI)” included to indicate the presence of the mutation. Activities of the mutated plasmid constructs are reported relative
to that of pBS. ND, not done.
FIG. 2. Deletion analysis of pB720-1217 in LMH cells. The diagram at the
top represents pBS with the region downstream of nucleotide coordinate 720
enlarged. The arrow indicates the transcriptional start site at DHBV coordinate
984. Horizontal lines and plasmid designations are as described in the legend to
Fig. 1. The asterisk indicates that activity from this construct could not always be
distinguished from the background activity of the pCATBasic plasmid.
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the region immediately upstream of the initiation site for S was
fully capable of activating transcription and imparting liver
specificity in transient-expression assays, this region was exam-
ined for sequences that displayed similarities to known hepa-
tocyte-enriched regulatory proteins. A striking match to the
HNF3 consensus recognition site (20) was located on the
DHBV antisense strand, at positions 225 to 236 (nucleotide
coordinates 948 to 959) relative to the mRNA initiation site for
S at nucleotide 984 (Fig. 3). EMSAs were conducted to eval-
uate the affinity and specificity of this sequence for DNA-
binding proteins contained in nuclear extracts from LMH cells.
The double-stranded oligonucleotides used in these assays are
shown in Fig. 3.
In EMSA, proteins extracted from LMH nuclei specifically
bound the 945-959 probe, as demonstrated by the addition of
unlabeled double-stranded oligonucleotide 945-959 or unla-
beled double-stranded TTR oligonucleotide (Fig. 4, lanes 2 to
4), which contained a known high-affinity HNF3 binding site
from the transthyretin promoter (7). Addition of an unlabeled
double-stranded oligonucleotide specific for Sp1 failed to in-
hibit the formation of complexes (lane 5).
To determine the extents to which the DNA-protein inter-
actions in Fig. 4 were characteristic of differentiated liver cell
lines, we used the labeled 945-959 oligonucleotide with extracts
prepared from the cell lines used in the transient-expression
assays (Fig. 5). LMH and HepG2 nuclear extracts displayed
similar specific interactions with the 945-959 probe (lanes 2 to
5), whereas these specific complexes were not detectable in
reactions with HepG2.1 or HeLa extracts. HeLa extracts oc-
casionally produced a low level of a complex which migrated
more slowly than those formed with LMH or HepG2 extracts;
however, this complex was inconsistently inhibited by the ad-
dition of unlabeled 945-959 oligonucleotide. The apparent liv-
er-enriched distribution of the proteins interacting with probe
945-959 together with the demonstrated specificity of the
DNA-protein interactions supported the contention that pro-
teins with properties similar to HNF3 were capable of recog-
nizing this DHBV sequence in these assays.
Deletion of the putative HNF3 recognition sequence drasti-
cally reduces expression from the S promoter. Sequence in-
spection and EMSAs indicated that the identified sequence
might be a binding site for HNF3. However, those experiments
did not address the functional contribution of the site in the
context of the S promoter, and such a determination could not
be made from the constructs used for the earlier transient-
transfection experiments. Therefore, this region was further
analyzed with additional 59 deletions of pB720-1178 (Fig. 6).
Deletion of sequence directly upstream of the potential
FIG. 3. Nucleotide sequence of the DHBV S promoter region. The nucleotide coordinates are derived from the GenBank database, and their positions relative to
the transcription initiation site at nucleotide 984 (indicated with an arrow) are shown in parentheses. The sequences present in the DHBV oligonucleotides (DHBV
oligo) (top strand only) are indicated and are designated according to the coordinates of the DHBV sequences present. Sequences of the oligonucleotides representing
consensus binding sites are shown boxed. TTR (HNF3) is a previously characterized HNF3 binding site from positions 285 to 2111 of the mouse transthyretin
promoter. Sp1 is the consensus recognition sequence for the Sp1 transcription factor. The binding site within each of those oligonucleotides is underlined. The HNF3
consensus recognition sequence is aligned with the DHBV S promoter candidate HNF3 binding site at positions 225 to 236, and identical nucleotides are indicated
(K is G or T; R is A or G; V is A, C, or G; W is A or T; and Y is C or T). Also shown is an alignment between the HNF3 consensus recognition sequence and the
sequence from DHBV oligonucleotide 961-983 around the TGTTT core.
FIG. 4. EMSA and complex inhibition analysis of the radiolabeled double-
stranded oligonucleotide 945-959 from the DHBV S promoter. LMH nuclear
extracts were analyzed for their ability to form complexes with probe 945-959,
and unlabeled double-stranded oligonucleotides were used as competitor DNAs
to demonstrate the specificity of the observed complexes. Lane 1, no nuclear
extract and no competitor (control); lane 2, no competitor (control).
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HNF3 site to produce pB934-1178 did not significantly affect
reporter gene activity in LMH cells, which indicated that the
signal registered from pB720-1178 was primarily dependent
upon sequences downstream of nucleotide 934. In contrast,
CAT expression from pB957-1178 was reduced more than 40-
fold from that of pB934-1178. Since the deletion of sequence
between DHBV coordinates 720 and 934 had no significant
effect on reporter gene activity, whereas the subsequent dele-
tion to coordinate 957 produced a severe effect, we concluded
that pB934-1178 represented a minimal S promoter in these
transient-expression assays and that the region between coor-
dinates 934 to 957 spanned a significant transcriptional regu-
latory element.
Exogenous expression of HNF3 turns on the S promoter in
HepG2.1 cells. The preceding data strongly suggested an es-
sential role for the region between coordinates 934 and 957 in
transcription from the DHBV S promoter, and EMSA results
indicated that this sequence might harbor a binding site for
members of the HNF3 family. To assess the functional re-
sponse of the DHBV S promoter to HNF3 transcription fac-
tors, we transfected HepG2.1 cells with a rat HNF3b expres-
sion plasmid in concert with several S promoter constructs
(Fig. 7). The effect of supplying HNF3b in trans was profound.
In all cases in which the putative HNF3 recognition sequence
was present, HNF3b was capable of activating the reporter
FIG. 5. DNA-protein complexes formed with extracts from different cell
lines (L, LMH; G2, HepG2; 2.1, HepG2.1; He, HeLa) and radiolabeled 945-959.
Unlabeled double-stranded oligonucleotide 945-959 was used to demonstrate the
specificity of the observed complexes. Extract was omitted from lane 1 (2). The
asterisk indicates the position of a frequently seen nonspecific band visible in
lanes 4, 5, 8, and 9.
FIG. 6. Deletion analysis of pB720-1178 in LMH cells. The diagram at the top of the figure represents construct pB720-1178. The black boxes represent the positions
of the HNF3 binding site and the CAT open reading frame. The arrow indicates the site of transcription initiation at DHBV coordinate 984. Horizontal lines and
plasmid designations are as described in the legend to Fig. 1.
FIG. 7. Exogenous HNF3b activates the DHBV S promoter in HepG2.1
cells. Activities of the DHBV S promoter constructs are reported in the absence
(2) or presence (1) of expressed HNF3b. Since the DHBV S promoter con-
structs were inactive in this cell line in the absence of expressed HNF3b, CAT
activities in the presence of the expressed protein are not reported as fold
transactivation. Instead, the normalized CAT activities of each of the S promoter
plasmids in the presence of HNF3b are depicted as the average percent acety-
lation obtained from three experiments.
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gene, with normalized CAT activities ranging from 13 to 35%.
Since HepG2.1 cells previously were not capable of supporting
transcription from these promoter constructs and did not do so
in the presence of the pCMV vector control (Fig. 7), it ap-
peared that the presence of HNF3b was a critical factor in
switching these DHBV S promoter constructs from an inactive
to an active state. The two constructs lacking the candidate
HNF3 site (pB957-1178 and pB1094-1178) appeared to pos-
sess some level of independent activity in this cell line, but they
did not exhibit any responsiveness to HNF3b. The inability of
HNF3b to mediate induction of the reporter gene when se-
quences upstream of coordinate 957 were absent implies that a
functional site was no longer available in those plasmids.
Exogenously expressed HNF3 shifts the 945-959 probe in a
manner identical to that of liver cell nuclear extracts. Previ-
ously, we determined that the 945-959 probe bound nuclear
proteins in a cell type-specific manner (Fig. 4 and 5), corre-
sponding to the expression profile observed in transient-trans-
fection experiments (Fig. 1). Cotransfection of HepG2.1 cells
with a rat HNF3b expression plasmid and S promoter con-
structs resulted in transactivation of the S promoter, appar-
ently through the identified HNF3 motif (Fig. 7). We used
nuclear extracts derived from HepG2.1 cells transfected with
vectors expressing rat HNF3a or rat HNF3b in conjunction
with the labeled double-stranded oligonucleotide 945-959 in
EMSA to confirm the ability of these expressed proteins to
interact with this sequence (Fig. 8).
Expression of either HNF3a or HNF3b resulted in the for-
mation of complexes with migration and competition proper-
ties similar to those seen with extracts from LMH nuclei. These
complexes were not observed when extracts from HepG2.1
cells transfected with the empty expression vector pCMV were
used (data not shown). Since the HNF3 proteins exist in liver
cells as a family of closely related polypeptides with slightly
different migration properties (20), these proteins frequently
appear as an elongated complex rather than a discrete band in
these types of assays. This probably accounts for exogenous
expression of either one of the proteins resulting in a more
distinct band than a complex formed with extracts from liver
nuclei. Unlabeled competitor oligonucleotides 945-959 or TTR
inhibited formation of the complexes (Fig. 8, lanes 3, 4, 8, and
9), though a small fraction of complex remained when com-
petitor oligonucleotide 945-959 was used (lanes 3 and 8). This
result is consistent with reports that have indicated that there
are both strong and weak affinity sites for HNF3 proteins (20)
and that recognition sequences containing a TGTTT core are
weak affinity sites (13, 20). The addition of either the unlabeled
double-stranded Sp1 consensus oligonucleotide or the DHBV
double-stranded 961-983 oligonucleotide had no effect (lanes
5, 6, 10, and 11). The inability of the latter oligonucleotide to
compete was interesting, as this oligonucleotide contained a
motif with a match at 9 of 12 positions to the HNF3 consensus
sequence, including a TGTTT core identical to the one con-
tained within double-stranded oligonucleotide 945-959 (Fig.
3). The inability of the 961-983 oligonucleotide to inhibit the
formation of complexes despite sequence similarity was a fur-
ther, albeit circumstantial, indication of the specific nature of
the interaction taking place between probe 945-959 and HNF3
proteins. Though complexes between LMH nuclear extracts
and labeled double-stranded oligonucleotide 961-983 could be
resolved during EMSA, these complexes did not comigrate
with the gels shown in Fig. 4, 5, or 8, and they were not
inhibited by the addition of unlabeled double-stranded oligo-
nucleotide 945-959 (data not shown). Use of equal amounts of
HNF3a and HNF3b together in a binding reaction with probe
945-959 produced a complex with an appearance and migra-
tion similar to the one formed by LMH nuclear extracts (Fig.
8, lane 12). Inhibition of the formation of this complex was the
same as in the assays using the individual polypeptides (data
not shown).
DISCUSSION
We present several lines of evidence indicating that HNF3-
like proteins play a critical role in transcription from the
DHBV S promoter and that this family of liver-enriched tran-
scription factors probably mediate their regulatory effects
through a binding site at positions 225 to 236 relative to the
cap site for the S transcript. The EMSA results demonstrated
the following. (i) An oligonucleotide containing the candidate
binding site specifically interacted with factors from the nuclei
of LMH and HepG2 cells but not those from HepG2.1 or
HeLa cells. (ii) The DNA-protein complexes formed with nu-
clear extracts from LMH and HepG2 cells comigrated. (iii)
Exogenously expressed rat HNF3 proteins formed specific
complexes with this oligonucleotide that comigrated with com-
plexes seen when LMH or HepG2 nuclei were used. Deletion
of the predicted HNF3 binding site from a minimal DHBV S
promoter construct caused a precipitous reduction in expres-
sion of a linked reporter gene in LMH cells. Furthermore,
cotransfection of HepG2.1 cells with HNF3 expression plas-
mids and DHBV S promoter constructs demonstrated that the
S promoter constructs which previously had been silent in this
cell line could be activated by HNF3 but only in cases where
the proposed HNF3 site was present. These data accord well
with our initial observation that expression from the S pro-
moter was dependent upon the environment of a differentiated
hepatocyte. Formal proof that HNF3 is acting at the identified
site is lacking, since antisera that would positively identify
HNF3 proteins from chicken liver nuclear extracts are not
available. However, the simplest explanation for our findings is
FIG. 8. Interaction of exogenously expressed HNF3a (a) and HNF3b (b)
proteins with radiolabeled double-stranded oligonucleotide 945-959 in EMSA.
Unlabeled double-stranded DNAs were used to determine the specificity of the
observed complexes. Extract abbreviations: L, LMH; 2.1a, HepG2.1 cells trans-
fected with pCMVHNF3a; 2.1b, HepG2.1 cells transfected with pCMVHNF3b;
2.1a,b, equal amounts of 2.1a and 2.1b extract mixed in the same binding
reaction mixture. Lane 1 is from a longer exposure of the same gel. Competitor
was not present (2) in some lanes, as indicated below the gels.
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that an HNF3-like protein(s) is an important determinant in
regulating transcription from the DHBV S promoter.
Our observation that transcriptional activity from the
DHBV S promoter was retained in the absence of the DHBV
enhancer region at nucleotide coordinates 2172 to 2355 (9, 17)
differs significantly from a previous report (17). In that analy-
sis, inclusion of the enhancer segment was essential to detec-
tion of activity from the S promoter in transient transfections
into LMH cells. In the current study, removal of the enhancer
region from the unit-length genomic construct did not diminish
transcriptional activity in LMH or HepG2 cells, which suggests
that perhaps other regions of the genome are more important
in regulating transcription from the S promoter. The reason for
such different results is not clear. The extents of the DHBV
sequences present in the plasmid constructs used are not likely
to account for the difference, as the DHBV sequences repre-
sented in our construct pB720-1217 are analogous to those in
pSGH (17), in which DHBV sequence from coordinates 718 to
1217 drives a human growth hormone reporter gene. DHBV
sequences in pSGH were derived from the DHBV16 sequence
(19). The DHBV16 genome differs from that of DHBV2.3 at 5
nucleotide positions between coordinates 718 and 1217.
Though these changes are scattered over the 500-bp region and
none of them fall within the HNF3 recognition sequence iden-
tified in the present study, it is nonetheless possible that the
difference in the two sequences accounts for the contrasting
outcomes. Alternatively, the difference in results may be a
consequence of the different reporter systems employed.
We noted consistently elevated levels of reporter gene ac-
tivity relative to that of the parent plasmid construct pBS for
the S promoter constructs in which the enhancer, the prege-
nome-nucleocapsid promoter, and significant portions of pre-
genome-encoding sequence were absent (Fig. 1A). Rather
than reflecting specific positive regulatory elements acting on
the DHBV S promoter, these data most likely result from
alleviating promoter occlusion, in which transcription from
downstream promoters is suppressed by strong upstream pro-
moters (10). Consistent with this interpretation are the obser-
vations of Huang and Summers (12) during characterization of
the DHBV pet sequence. They found that when the pregenome
promoter was deleted or inactivated by removal of pet, there
were corresponding increases in the levels of mRNA from the
downstream envelope promoters, as measured by Northern
(RNA) blot analysis and primer extension.
A mutation which incapacitates expression from the DHBV
pre-S promoter had no effect on the amount of reporter gene
expression directed by the downstream DHBV S promoter.
This was an important determination for two reasons. First, the
two promoters are close enough to one another to make pro-
moter occlusion a possibility in this case as well. The fact that
it is possible to inactivate the upstream promoter, in this case
pre-S, and not observe a corresponding increase in activity
from the downstream promoter indicates that transcriptional
interference from pre-S is not occurring in this system. A
similar result has been noted previously (12). Second, since
expression from pB428-1217 did not differ from pB428-
1217(PstI) (Fig. 1), we can conclude that the decrease in CAT
expression when sequence between coordinates 428 and 720
was deleted probably reflects removal of one or more elements
that modulate the activity of the minimal S promoter. If the
elevated activity of pB428-1217 had been a consequence of
transcriptional read-through from the pre-S promoter instead,
we would have expected that expression from pB428-
1217(PstI) be decreased in comparison. Thus, it appears that
though the fundamental components of the DHBV S promoter
are in the immediate proximity of the cap site for the S tran-
script, additional modulatory sequences may exist in the vicin-
ity of the DHBV pre-S promoter.
HNF3 proteins have been shown to be important regulators
in the liver-specific transcription of numerous genes expressed
mainly in hepatocytes (26) and in fact have recently been
reported to modulate the pre-S1 and nucleocapsid promoters
of HBV in transient-expression assays (14, 23). Several binding
sites for HNF3 have been identified in the DHBV enhancer as
well (8, 16, 18). In our transactivation experiments, the effect of
exogenous HNF3b on pBS is not as strong as its effect on
pB934-1178. In the context of the entire DHBV genome, the
exogenously expressed protein may be interacting with HNF3
recognition sequences present elsewhere in the DHBV se-
quence, though whether that would contribute to activation of
other DHBV promoters is not known. The lower induction of
pBS relative to those of the subsequent deletion constructs
mimics the general trend we observed with the S promoter
deletion constructs in the LMH and HepG2 cell lines. The fact
that induced activity did not decrease in going from pBS to
pB720-1178 to pB934-1178, together with the effects of dele-
tion analysis in LMH cells, strongly argues that the only HNF3
recognition sequence required in order to activate the DHBV
S promoter in these assays is the one at positions 225 to 236.
It is perhaps interesting that this location is normally where
one would expect to find the TATA motif.
Experiments from our laboratory have also indicated in vitro
binding sites for Sp1 downstream of the HNF3 site in the
DHBV S promoter (unpublished observations), though it re-
mains to be determined to what degree they are functional and
what role they may play in coordinating activity from this
promoter. As mentioned previously, Sp1 is capable of activat-
ing the HBV S promoter through several functional recogni-
tion sites in the S regulatory region (21), so it would not be
unexpected if DHBV were able to make use of this transcrip-
tion factor in regulating expression from the S promoter.
However, an interesting difference from HBV is the stringent
requirement that the DHBV S promoter displays for differen-
tiated hepatocyte cell lines (17; this study), whereas the HBV
S promoter is active in both HeLa and HepG2.1 cells as well as
other nonliver cell lines (4, 11, 21, 22, 25). Our observation that
the DHBV S promoter did not activate expression of CAT in
HeLa cells is consistent with a previous indication that the
DHBV envelope promoters may not be functional in HeLa
cells (12). Clearly, if ubiquitous transcriptional regulators, such
as Sp1, have a role regulating transcription from this promoter,
they are not capable of acting independently to promote tran-
scription as is the case for the HBV S promoter (21).
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